EUCTR2020-004940-27-BE进行中（未招募）1 期
A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects (PRIOH-1)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 153
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Immunocompromised (due to conditions including but not limited to HIV infection, hematopoietic cell or solid organ transplantation, and chronic use of immunosuppressive treatment) men and women of any ethnic group aged = 18 years.
- •2. ACV-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic ACV resistance testing for current lesion. Clinical failure is defined as no improvement after oral or iv doses for at least 7 days at doses equivalent to or greater than the local agency approved high doses of acyclovir, valacyclovir or Famciclovir.
- •3. Lesions accessible for visual inspection to allow assessment of lesion healing including visualization by endoscopy.
- •4. Willing to use highly effective birth control:
- •Male subjects must be surgically sterile (eg, vasectomy at least for the 26 weeks before starting treatment) or must agree to use an adequate method of contraception during sexual intercourse with women of childbearing potential to make sure the fathering of a child will be ruled out during treatment and for at least 6 months after the final dose of trial medication. Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before starting treatment) or postmenopausal (defined as spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone (FSH) in the postmenopausal range at start of treatment). Female subjects of childbearing potential must use an adequate method of contraception.
- •An adequate method of contraception is defined as a highly effective method of contraception plus use of a condom during participation in this trial and for at least 6,5 complete months after the final dose of foscarnet and 1 complete month after the last dose of pritelivir.
- •A highly effective method of contraception is defined as:
- •o copper intrauterine device,
- •o the levonorgestrel-releasing intrauterine system,
- •o the progestogen implant,
- •o combined (estrogen and progestogen containing) hormonal contraception (oral,
- •intravaginal, transdermal) associated with inhibition of ovulation,
- •o progestogen-only hormonal contraception (oral, injectable, implantable) associated
- •with inhibition of ovulation.
- •5. Subject, and/or their legally authorized representative, must be willing and able (in the opinion of the Investigator) to understand the Informed Consent Form.
- •6. Negative serum ß-HCG (beta-human chorionic gonadotropin) test for women of childbearing potential at Screening and a negative urine pregnancy test at Day 1.
- •7. Subject must give written informed consent. For subjects, who are unable to provide informed consent for whatever reason, written consent must be obtained from the legal representative.
- •Parts D (complete) and F:
- •Inclusion criteria in Part D are identical to those in Part C, except for inclusion criteria 2 which is replaced by:
- •2. ACV-R and foscarnet-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic resistance testing for current lesion or documented intolerance to foscarnet requiring cessation of foscarnet treatment or precluding foscarnet
- •treatment. Clinical failure of ACV treatment is defined as no improvement after oral or iv doses for at least 7 days at doses equivalent to or greater than the local agency approved high doses of acyclovir, valacyclovir, or famciclovir. Clinical failure of foscarnet treatment is defin
排除标准
- •1. Known resistance/intolerance to pritelivir or any of the excipients.
- •2. Previous treatment in PRIOH-1
- •3. Baseline safety laboratory abnormalities:
- •o ANC <1000 cells/mm3
- •o platelet count <25,000 cells/mm3
- •o hemoglobin <8.0 g/dL
- •o AST or ALT >5 x ULN
- •o bilirubin >2.5 x ULN
- •4. History or current evidence of gastrointestinal malabsorption which, in the opinion of the Investigator, may affect the extent of absorption of pritelivir.
- •5. Hemodialysis for any indication and ESRD (eGFR <15 mL/min; stage 5 CKD).
- •6. History or current evidence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrinological, metabolic, neurological, psychiatric, or other diseases, which, in the opinion of the Investigator, may affect the subject's safety orinterfere with the trial.
- •7. Abnormalities in hematological, clinical chemical or any other laboratory variables at Screening measured by the central or local laboratory regarded as clinically relevant by the Investigator unless they are due to underlying disease or condition.
- •8. Not able to communicate meaningfully with the Investigator and site staff.
- •9. Any other condition which in the opinion of the Investigator would interfere with successful completion of this clinical trial.
- •10. Any other local condition including bacterial superinfection which in the opinion of the Investigator would interfere with the efficacy evaluation.
- •11. Pregnant and/or breastfeeding women.
- •12. Having received an investigational drug in an investigational drug trial within 7 half-lives after the last administration of this drug before initiating trial medication. Current participation in a clinical trial without receiving other investigational drugs (eg, follow-upphase of a trial, observational study) is permitted. Other investigational drugs are also not permitted during participation in this trial.
- •Part D (complete)
- •All exclusion criteria as for Part C, except for exclusion criteria 1 and 12 which are replaced by:
- •1. Known intolerance to pritelivir or any of the excipients and
- •12. Having received an investigational drug in an investigational drug trial within 7 half-lives after the last administration of this drug before initiating trial medication, except for subjects entering Part D who have previously received foscarnet treatment in Part C of this trial. Participation in a clinical trial without receiving other investigational drugs (eg, follow-up phase of a trial, observational study) is permitted. Part E (Part E is not being conducted in Germany)All exclusion criteria as for Part C, with the addition of:
- •13. Having used acyclovir, valacyclovir, or famciclovir within 3 days prior to starting pritelivir.
- •All exclusion criteria for Part D plus
- •13. Part D open for enrollment
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to assess the efficacy and safety of pritelivir for the treatment of Herpes Simplex Virus infections on the skin and mucous membranes which is resistant to acyclovir in subjects with weakened immune system.Acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjectsEUCTR2020-004940-27-DEAiCuris Anti-infective Cures AG153
进行中（未招募）
1 期
A clinical trial to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of Herpes Simplex Virus infections on the skin and mucous membranes which is resistant to acyclovir in subjects with weakened immune system.Acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjectsMedDRA version: 20.0Level: HLTClassification code 10019972Term: Herpes viral infectionsSystem Organ Class: 100000004862EUCTR2020-004940-27-ITAiCuris Anti-infective Cures GmbH128
招募中
3 期
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects2023-510088-37-00AiCuris Anti-infective Cures AG54
进行中（未招募）
1 期
A clinical trial to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of Herpes Simplex Virus infections on the skin and mucous membranes which is resistant to acyclovir in subjects with weakened immune system.EUCTR2020-004940-27-GRAiCuris Anti-infective Cures AG128
招募中
1 期
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised SubjectsAcyclovir-resistant mucocutaneous HSV infections in immunocompromised subjectsMedDRA version: 20.0Level: LLTClassification code: 10063570Term: HSV infection Class: 10021881CTIS2023-510088-37-00AiCuris Anti-infective Cures AG144